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httpicense.Abstract The aim was to develop and optimize fast dissolving oro-dispersible ﬁlms of granisetron
hydrochloride (GH) by two-factor, three-level Box–Behnken design as the two independent vari-
ables such as X1 (polymer) and X2 (plasticizer) were selected on the basis of the preliminary studies
carried out before the experimental design is being implemented. A second-order polynomial equa-
tion to construct contour plots for the prediction of responses of the dependent variables such as
drug release (Y1), Disintegration time (Y2), and Y3 (Tensile strength) was studied. The Response
surface plots were drawn, statistical validity of the polynomials was established to ﬁnd the compo-
sitions of optimized formulation which was evaluated using the Franz-type diffusion cell. The
designs establish the role of the derived polynomial equation and contour plots in predicting the
values of dependent variables for the preparation and optimization.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
Open access under CC BY-NC-ND license.1. Introduction
The ultimate goal of any drug delivery system is the success-
ful delivery of the drug, in which almost 90% of the drugs are
administered to the body for the treatment of various disor-
ders and diseases as it is regarded as the safest, most conve-
nient and most economical method of drug delivery having
the highest patient compliance.1–3 In this the drug is dissolvedom (H. Chaudhary).
aculty of Pharmacy, Cairo
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://dx.doi.org/10.1016/j.bfopcu.201or swallowed and then enters into the systemic circulation to
produce the desired effect.4,5 Despite of astounding advance-
ment in drug delivery the oral route of drug administration is
considered as the most important method of administration
of drug for systemic effect because of self medication, ease
of administration and avoidance of pain compared to paren-
teral route.6–9
1.1. Anatomy of oral cavity
Oral cavity offers a unique environment for delivering the
drugs (Fig. 1). The oral mucosa allows direct access of drug
to the systemic circulation and avoids ﬁrst pass metabolism.
The epithelium of the oral cavity is quite similar to that of
the skin, with slight differences with regard to keratinization,
protective and lubricant mucous which is spread across itsaculty of Pharmacy, Cairo University.
3.05.002
Figure 1 Sectional view of oral cavity and anatomy of oral cavity (http://www.edoctoronline .com/zmedical-atlas.asp?c=4&id=21667).
194 H. Chaudhary et al.surface.10 The permeability of oral mucosa is 4–1000 times
greater than that of the skin. The oral cavity is divided into
two regions: outer being the oral vestibule bounded by the lips
and cheeks; the hard and soft palates, the ﬂoor of the mouth
and tonsils.11 It is the forceful expulsion/discharge of gastric
contents, or may be a protective physiological mechanism, that
prevents entry of potentially harmful substances into the gas-
trointestinal tract. Vomiting can lead to dehydration, bleeding,
severe alkalosis and rarely esophagus perforation irrespective
of the cause of vomiting. Vomiting is to be differentiated from
retching, regurgitation or rumination. Retching involves the
same physiological mechanisms as vomiting, but it occurs
against a closed glottis and there is no expulsion of gastric con-
tents. Regurgitation is the return of small amounts of food or
secretions to the pharynx in the form of mechanical obstruc-
tion of the esophagus. Rumination is similar to regurgitation,
except small amounts of completely swallowed food are re-
turned to the hypopharynx from the stomach and is often
re-swallowed. The vomiting reﬂex is triggered by the stimula-
tion of chemoreceptors in the upper gastrointestinal tract
(GIT) and also the mechanoreceptors in the wall of the GIT
which are activated by both contraction and distension of
the gut as well as by physical damage. A coordinating center
which is present in the central nervous system controls the
emetic response. This center is located in the lateral medullary
region of the brain. Afferent nerves to the vomiting center arise
from abdominal splanchnic and vagal nerves, vestibulo-laby-
rinthine receptors, the cerebral cortex and the chemoreceptor
trigger zone (CTZ). The CTZ is exposed to emetic stimuli of
endogenous origin such as hormones associated with preg-
nancy and to stimuli of exogenous origin such as drugs.12 Oral
drug delivery has been known for decades as the most widely
utilized route of administration among all the routes that have
been explored for the systemic delivery of drugs via various
pharmaceutical products of different dosage forms. The devel-
opment of a pharmaceutical product for oral delivery irrespec-
tive of its physical forms (solid, semisolid, or oral liquid dosage
form) involves varying extents of optimization of dosage
form.131.2. Fast dissolving drug delivery system (FDDS)
Fast dissolving drug delivery system is a new generation delivery
system also known as fast dissolving/disintegrating ﬁlm for the
oral delivery of the drugs which came into existence in the late
1970’s as an alternative to tablets, capsules, syrups andother for-
mulations for pediatric and geriatric patients, who experience
difﬁculties in swallowing traditional solid dosage forms which
combines both the advantages of conventional tablet and of li-
quid formulation.14 FDDS is easy to administer and provides
better patient compliance in the elderly, pediatric, mentally re-
tarded, nauseated and uncooperative paients.15 This delivery
system consists of the solid dosage forms that dissolve quickly
i.e. within a matter of seconds in the oral cavity without the
administration of water. The delivery system consists of a very
thin oral strip which is simply placed on the patient’s tongue
or any other oral mucosal tissue and instantly gets wetted by sal-
iva.16 The ﬁlm rapidly hydrates onto the site of application. It
then rapidly dissolves anddisintegrates to release themedication
for oro-mucosal absorption. Fast dissolving oral thin ﬁlms are
widely accepted by patients and also to the caregiver for their
ease-of-delivery, portability and accurate dosing.17 The robust-
ness of the ﬁlm depends upon the type and amount of polymer
used and general dissolution time for orally dissolving ﬁlm is
5–20 min. as per pharmacopoeia.18,19 They also provide quick
onset of action within few seconds as the oro-mucosal absorp-
tion of drug occurs directly from the site of administration to
the systemic circulation avoiding ﬁrst pass metabolism to pro-
duce the desired effect.202. Materials and Methods
Granisetron Hydrochloride (GH) was pure (100.2% w/w
granisetron according to analysis by manufacturer) and
was received from Natco Pharma, Hyderabad (India).
Hydroxypropyl methyl cellulose 15 cps, Saccharin sodium
and polyvinyl pyrrolidone K-30 were obtained from Central
Drug House (Delhi, India). Oil of peppermint and glycerin
Development and optimization of fast dissolving oro-dispersible ﬁlms of granisetron HCl 195was bought from SD Fine-Chem limited, Mumbai, India. All
the analytical grade materials and double distilled water were
used throughout the study.
2.1. Preliminary trials
2.1.1. Selection of polymer
Polymers such as, HPMC and pullulan were tried for the prep-
aration of fast dissolving oro-dispersible ﬁlms (FDF). Pullulan
did not show a good result at 40–50% concentration, whereas
ﬁlms of HPMC in a range of 40% did not give a good ﬁlm (the
ﬁlm was not easily peelable) and at 50% concentration, the
ﬁlm was sticky in nature. Hence all the percentage between
40–50% was trailed of HPMC. A range of 45–50% was
selected for the formulation of ﬁlms.
2.1.2. Selection of plasticizer
Various plasticizers were selected and trails were done. Propyl-
ene glycol below 15% did not show good ﬁlm properties as was
tested by the folding endurance of the ﬁlm. Hence, a range of
plasticizer (propylene glycol) was used in the range of 15–20%.2.2. Preparation of fast dissolving ﬁlms (FDF)
The required percentage of polymer solution was prepared by
dispersing the polymer powder in distilled water with continu-
ous stirring. After continuous stirring the solution was left
undisturbed for three to four hours to remove all the air bub-
bles. Accurately weighed quantity of drug, plasticizer and all
other excipients was separately dissolved in distilled water in
another beaker. After complete hydration of the polymer withTable 2 Design (Box–Behnken) of experiments with results.
Runs Batch Independent variable D
O
X1 X2 Y
1 FF1 1 1 98
2 FF2 0 0 95
3 FF3 1 0 92
4 FF4 0 0 95
5 FF5 1 1 92
6 FF6 0 0 95
7 FF7 0 1 95
8 FF8 1 1 92
9 FF9 0 1 94
10 FF10 1 0 98
11 FF11 1 1 98
12 FF12 0 0 95
13 FF13 0 0 95
X1 = Concentration of polymer (% w/w); X2 = concentration of plastic
Y3 = tensile strength (N/m
2).
Table 1 Independent variables in design.
Factor Level us
Independent variables Low (
X1 = Concentration of polymer (% w/w) 45.0
X2 = Concentration of plasticizer (% w/w) 15.0water, drug-plasticizer and all other excipient solutions were
added and mixed thoroughly, and the volume was made up
ten milliliters with distilled water. The polymeric solutions
were then poured on the mold, allowed to dry and stored in
aluminum foil. The different formulations were prepared
incorporating polymer (45–50% w/w), plasticizer (15–20% w/
w), and water using Box–Behnken experimental design and
optimized formulation was generated using statistical screen-
ing. The thirteen runs of the experiment were evaluated for
the percentage drug release (Y1), disintegration time (Y2),
and tensile strength (Y3) and are listed in Table 2.
2.3. Determination of evaluation parameters
Properties such as homogeneity, color, transparency and sur-
face of the oral ﬁlms were evaluated by visually inspection.2
The ﬁlm strip (2 · 2 cm) of GH was dissolved in phosphate
buffer pH 6.8. The solution was suitably diluted and was ana-
lyzed by UV-Visible spectrophotometer at 302 nm.21 The
thicknesses of ﬁlm formulation were evaluated by using
micrometer screw gauge. The thicknesses of six ﬁlms were ta-
ken and then average thickness was calculated.22 The ﬁlm
(2 · 2 cm) was cut and weight of each ﬁlm was taken in tripli-
cate and the difference in weight variation of ﬁlm was noted.23
The surface pH of ﬁlms was evaluated by placing the ﬁlm in a
petridish, slightly wet with the help of distilled water (as an
acidic or alkaline pH may cause irritation of the oral mucosa,
the surface pH of the ﬁlm was kept neutral) at room tempera-
ture. The pH was noted by bringing the surface of the ﬁlm in
contact with pH meter electrode for one min. and average of
fast dissolving ﬁlms (FDF) was taken in triplicate.2 The pre-
pared ﬁlms were folded at the same place number of times untilependent variables
bserved value Predicted value
1 Y2 Y3 Y1 Y2 Y3
.0 28.0 0.161 97.98 28.12 0.160
.5 26.0 0.179 95.30 26.90 0.180
.5 40.0 0.183 92.57 39.43 0.181
.2 27.0 0.181 95.30 26.90 0.180
.0 39.0 0.167 91.98 39.45 0.170
.2 28.0 0.181 95.30 26.90 0.180
.0 30.0 0.185 95.07 30.09 0.190
.5 45.0 0.190 92.45 45.12 0.190
.8 30.0 0.167 94.83 29.43 0.170
.3 23.0 0.172 98.33 23.09 0.170
.0 24.0 0.175 97.98 23.79 0.170
.4 26.0 0.181 95.30 26.90 0.180
.4 27.0 0.181 95.30 26.90 0.180
izer (% w/w); Y1 = drug release (%); Y2 = disintegration time (s);
ed, actual (coded)
1) Medium (0) High (+1)
47.5 50.0
17.5 20.0
Figure 2 Fast dissolving ﬁlm of GH.
196 H. Chaudhary et al.it broke. By the number of times a ﬁlm is folded at the same
place without cracking or breaking revealed the best endur-
ance.24 The formulated fast dissolving ﬁlms (FDF) were
weighed initially and placed in a desiccator containing anhy-
drous calcium chloride for three days. After three days, the fast
dissolving ﬁlms (FDF) were taken out and weighed again. The
percentage moisture loss was calculated according to the
formula25:
Percentage moisture loss ¼ initial weight
 final weight=initial weight
The fast dissolving ﬁlms (FDF) free of imperfections were
held between two clamps at a distance of three centimeters
with a two kilogram load cell. The ﬁlm was pulled at a rate
of 100 mm/min and force required to break the ﬁlm was mea-
sured when the ﬁlm broke.26
2.4. Design of experiments
Box–Behnken designs are experimental designs for response
surface methodology devised by George E.P. Box and D.
Behnken in 1960. The Box–Behnken design for three factors
involves three blocks in each of which 2 factors are varied
through the four possible combinations of high and low. It is
necessary to include center points as well (in which all factors
are at their central values). A 2-factor, 3-level design used isTable 3 Data of evaluation parameters.
Formulation code Drug content (%) Thickness (mm) We
FF1 98.91 0.18 67.
FF2 98.63 0.23 67.
FF3 99.45 0.26 69.
FF4 98.91 0.23 67.
FF5 98.63 0.23 70.
FF6 98.63 0.23 67.
FF7 99.45 0.24 69.
FF8 98.91 0.30 68.
FF9 98.91 0.24 69.
FF10 99.72 0.21 68.
FF11 99.72 0.22 69.
FF12 98.63 0.23 67.
FF13 98.63 0.23 67.suitable for exploring quadratic response surfaces and con-
structing polynomial models with Design Expert version
8.0.7.1 The two independent variables such as polymer (X1)
and plasticizer (X2) were selected on the basis of the prelimin-
ary studies carried out before the experimental design is being
implemented. The experimental design was applied to investi-
gate the effect of different independent variables such as X1,
and X2. The interaction term (X1X2) shows how the response
changes when two factors are changed simultaneously. The
polynomial terms ðX21X22Þ are included to investigate nonlinear-
ity.27,28 The design of experiments generated polynomial equa-
tion, is given as;
Y ¼ b0 þ b1X1þ b2X2 þ b12X1X2 þ b11X21 þ b22X22
where, Yo is the dependent variable; bo is the intercept; b1–b22
are the regression coefﬁcients computed from the observed
experimental values of Y; and X1, X2 are the coded levels of
independent variables. A total of 13 runs were generated, se-
lected independent variables were polymer concentration (X1)
and plasticizer concentration (X2) and the levels of each factor
were low, medium, and high as listed in Table 1. The amount
of polymer concentration (X1) and plasticizer (X2) used to pre-
pare each of the formulations and their observed and predicted
responses are given in Table 2.
2.5. In-vitro drug permeation
Permeation studies were carried out in order to calculate the
percentage amount of drug permeating through the oral
mucosa.
2.5.1. Selection of oral mucosa
A speciﬁc methodology was employed to study buccal drug
absorption/permeation characteristics, special attention is war-
ranted to the choice of experimental animal species for such
experiment. For investigations, many researchers have used
rats and hamsters.29,30 The oral mucosa of larger experimental
animals that has been used for permeability and drug delivery
studies include monkey, dog and pigs.31 Porcine oral mucosa
was used as the model membrane. The buccal pouch of the
freshly killed pig was procured from the local slaughter house.
The buccal mucosa was excised and trimmed evenly from the
sides and then washed in an isotonic phosphate buffer of pH
6.8 and used.ight variation (mg) Surface pH Folding moisture
Endurance Loss (%)
33 7.13 192 7.12
00 6.90 202 4.47
33 6.70 392 4.61
00 6.90 202 4.47
00 6.63 356 7.14
00 6.90 202 4.47
33 6.73 237 7.50
67 6.70 402 4.65
33 6.73 237 7.50
67 6.87 202 6.98
33 6.87 260 3.89
00 6.90 202 4.47
00 6.90 202 4.47
Figure 3 In-vitro drug release proﬁles of fast dissolving ﬁlms.
Figure 4 Contour plot showing the effect of polymer concen-
tration (X1) and plasticizer (X2) on response Y1.
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Ex-vivo permeation studies were carried out through porcine
oral mucosa using modiﬁed Franz diffusion cell. The system
consisted of donor chamber and receptor chamber, jacket,
and sampling port. The buffer was warmed with the in built
heater and then assembly was set thermostatically at 37 C.
A Teﬂon coated mini magnetic bead was placed in the receiver
compartment for agitating the contained vehicle at 50 rpm (i.e.
rotations/min of magnetic bead within diffusion cell). The
receptor compartment was ﬁlled with vehicle, containing phos-
phate buffer pH 6.8. Receptor ﬂuid was sonicated to remove
dissolved gases and equilibrated at 37 C before placing in
the receptor compartment. Porcine oral mucosa was used as
the model membrane. The mucosa was mounted between the
donor and receptor compartments. The receptor compartment
was ﬁlled with 15 ml of isotonic phosphate buffer of pH 6.8
and the hydrodynamics were maintained by stirring with a
magnetic bead at 50 rpm. Optimized ﬁlm of dimensions
2 · 2 cm loaded with one mg of drug, previously weighed
was placed in intimate contact with the mucosal surface of
the membrane that was previously moistened with a few drops
of phosphate buffer. The donor compartment was ﬁlled with
1 ml of phosphate buffer of pH 6.8. Samples were withdrawn
at suitable intervals of 5, 10, 15, 20, 25 and 30 min, replacing
the same amount with the fresh medium.
2.6. Data analysis
Statistical validation of the polynomial equation generated by
Design Expert version was established on the basis of ANO-
VA provision in the software. A total of 13 runs (FF1–FF13)Table 4 Summary of results of quadratic model for regression ana
Quadratic model R2 Adjusted R2
Y1 0.9987 0.9978
Y2 0.9931 0.9881
Y3 0.9986 0.9976
Polynomial equations
Y1 ¼ 95:30 2:88X1 þ 0:12X2 þ 0:12X1X2 þ 0:15X21  0:35X22
Y2 ¼ 26:90þ 8:17X1 þ 0:33X2 þ 2:50X1X2 þ 4:36X21 þ 2:86X22
Y3 ¼ 0:18þ 5:500X1 þ 9:333X2 þ 2:000X1X2  3:155X21  4:655X22with triplicate center points were generated. The resultant
experimental data of response properties were compared with
those of the predicted values.
3. Result and discussion
3.1. Optimizations of independent variables
HPMC in a range of 45–50% was selected for the formulation
of fast dissolving ﬁlms (FDF). It was found that on increasing
the amount of polymer above 50% the percentage drug release
and disintegration time kept on increasing; while at 40% the
disintegration time kept on decreasing. Plasticizer was selected
in the range of 15–20%. Since above 20% FDF became stick-
ier and below 15% the ﬁlm did not show good ﬂexibility of
FDF.
3.2. Characterization of fast dissolving ﬁlms (FDF)
Granisetron HCl (GH) oro-dispersible ﬁlms prepared were
transparent, colorless, thin, and soft, with no spot on the ﬁlm
surface (Fig. 2). The prepared FDF was evaluated according to
the following parameters: % drug content, thickness, weight
variation, surface pH, folding endurance and percentage mois-
ture loss as shown below in Table 3.lysis of responses Y1, Y2, and Y3.
Predicted R2 SD %CV
0.9963 0.096 0.10
0.9760 0.74 2.44
0.9942 0.043 0.23
Figure 5 Contour plot showing the effect of polymer concen-
tration (X1) and plasticizer (X2) on response Y2.
Figure 6 Contour plot showing the effect of polymer concen-
tration (X1) and plasticizer (X2) on response Y3.
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The ex-vivo release proﬁles of ﬁlms were calculated and the
cumulative amount of drug release was found, the results are
demonstrated in Fig. 3. Drug release proﬁles of formulations
F1, show an initial phase of release of the drug having low
polymer amounts to spread the network of hydrophilic chain
around matrix system. The formulation FF10 showed fast re-
lease due to the less amount of polymer and plasticizer and
minimum in FF5 which was having the highest percentage of
polymer which will form a layer around the drug and allow
the drug to release at a slow pace. The inﬂuences of polymer
levels are found to be vital in regulating the drug release.
3.4. Fitting model to the data
Box–Behnken statistical experimental design as the RSM re-
quires 13 runs. The ranges of Y1 ,Y2 and Y3 are 92.00–
98.30%, 23.00–45.00 s and 0.16–0.19 N/cm2, respectively. For
all the responses observed for 13 formulations prepared were
simultaneously ﬁtted to ﬁrst order, second order and quadratic
models using Design Expert. It was observed that the best-ﬁt-
ted model was quadratic and the comparative values of R-
squared, SD, and % CV are given in Table 4 along with the
regression equation generated for each response. It is evident
that all the two independent variables, namely the concentra-
tion of polymer (X1), concentration of plasticizer (X2), respec-
tively have interactive effects on the three responses, Y1, Y2
and Y3. A positive value represents an effect that favors the
optimization, while a negative value indicates an inverse rela-
tionship between the factor and the response.
3.5. Contour plots and response surface analysis
Two dimensional contour plots were prepared for all the three
responses and are shown in Figs. 4–6 for responses Y1, Y2 andY3, respectively. These plots are known to study the interaction
effects (studying the effects of two factors at one time) of the
factors on the responses. Linear regression plots between the
observed and predicted values of the response properties were
drawn (Fig. 7a–c). The linear correlation plots demonstrated
high values of R-squared for all the three responses drawn be-
tween the predicted and experimental values. The R-squared
values of Y1, Y2 and Y3 were found to be in the range of
0.9963–0.9978, 0.9960–0.9981 and 0.9942–0.9976, respectively.
3.5.1. Response 1 (Y1): effect on drug release
The model proposes the following polynomial equation for
Drug Release
Y1 ¼ 95:30 2:88X1 þ 0:12X2 þ 0:12X1X2 þ 0:15X21  0:35X22
where, Y1 is drug release, X1 is the polymer concentration, and
X2 is the concentration of plasticizer. The Model F-value of
1100.58 implies themodel is signiﬁcant p<<0.0001. Therefore
this model can be used to navigate the design space. The contour
plots (Fig. 4) showed the effect of different independent vari-
ables on percentage drug release (Y1). Percentage drug release
decreases as the amount of polymer increases form 45% to
50% since the drug remains inside the polymer matrix and vice
versa.32 The increase in rate of drug release at 45% could be ex-
plained by the ability of the hydrophilic polymers to absorb
water, thereby promoting the dissolution, and hence the release,
of the highly water-soluble drug. Moreover, the hydrophilic
polymers would reach out and hence, create more pores and
channels for the drug to diffuse out of the patches.33
The drug release pattern in the fast dissolving ﬁlms (FDF) is
also affected by the concentration of plasticizer (X2) and fol-
lowed a direct relationship when the amount of plasticizer in-
creases. A positive value for the coefﬁcient (above mentioned
equation) is an indicative of the favorable effect whereas a nega-
tive value for the coefﬁcient indicates an unfavorable effect.
There is only a very little such as 0.01% chance that a ‘‘Model
Figure 7 Linear correlation plots (a, b, and c) between actual and predicted values.
Table 5 Evaluation of physical and chemical stability of optimized batch (FF10) at 40˚ ± 2˚ C/75 ± 5% RH as per ICH Q1A (R2)
guidelines stability studies.
Time (days) Physical change Chemical change
Appearance Weight variation Drug content Surface pH
0 Not changed 68.67 99.72 6.87
15 Not changed 68.33 99.45 6.80
30 Not changed 68.21 98.91 6.73
60 Not changed 68.00 98.63 6.70
90 Not changed 67.33 98.58 6.63
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‘‘Prob > F00 < 0.0500 indicate model terms are signiﬁcant and
values >0.1000 indicate the model terms are not signiﬁcant. If
there are many insigniﬁcant model terms, model reduction may
improve your model. The ‘‘Lack of Fit F-value’’ of 0.44 implies
the Lack of Fit is not signiﬁcant relative to the pure error.3.5.2. Response 2 (Y2): effect on disintegration time
The following polynomial equation prevailed from the model
for disintegration time.
Y2 ¼ 26:90þ 8:17X1 þ 0:33X2 þ 2:50X1X2 þ 4:36X21 þ 2:86X22
Figure 8 Determination of shelf life.
200 H. Chaudhary et al.where, Y2 is disintegration time. All the formulation showed re-
sponse of Y2 < 60 s. The Model F-value of 200.36 implies the
model is signiﬁcant p< 0.0001. The ‘‘Lack of Fit F-value’’ of
0.48 implies the Lack of Fit is not signiﬁcant relative to the
pure error. There is a 71.45% chance that a ‘‘Lack of Fit
F-value’’ this large could occur due to noise. Values of
‘‘Prob > F’’ < 0.0500 indicate model terms are signiﬁcant. In
this case X1, X2, X1 X2, X
2
1 X
2
2 are signiﬁcant model terms. As
the concentration of both the independent variables (X1 and
X2) increases resulted dependent variable showed a positive re-
sponse which is illustrated in Fig. 5 (as the amount of polymer
and plasticizer increases the disintegration time also increases).
3.5.3. Response 3 (Y3): effect on tensile strength
The polynomial equation for tensile strength was as follows
Y3 ¼ 0:18þ 5:500X1 þ 9:333X2 þ 2:000X1X2  3:155X21
 4:655X22
where, Y3 is the tensile strength. All the formulation showed
the response of Y3, 0.160–0.190. The Model F-value of 1005 ta-
ken out and weighed again 43 implies the model is signiﬁcant
(p< 0.0001). There is only a 0.01% chance that a ‘‘Model F-
Value’’ this large could occur due to noise. In this case X1, X2,
X1 X2, X
2
1 X
2
2 were signiﬁcant model terms and response
showed a positive response due to increases in impart ﬂexibility
to the ﬁlm i.e. as the amount of polymer and plasticizer in-
creases the tensile strength also increases(Fig. 6). Values
>0.1000 indicate the model terms are not signiﬁcant. The
‘‘Lack of Fit F-value’’ of 0.66 implies the Lack of Fit is not sig-
niﬁcant relative to the pure error and there is 61.88% chance
that a ‘‘Lack of Fit F-value’’ could occur large due to noise.
Non-signiﬁcant lack of ﬁt is good, we want the model to ﬁt.3.6. Optimization model validation
Statistical validity of the polynomials was established on the
basis of ANOVA provision in the Design Expert software.
Subsequently, the feasibility and grid searches were performed
to locate the composition of optimum formulations. The con-
tour plots were constructed using the output ﬁles generated bythe Design Expert software. After developing the polynomial
equations for the responses Y1, Y2 and Y3 with the indepen-
dent variables X1 and X2, the formulation was optimized. Opti-
mization was performed to ﬁnd out the level of independent
variables (X1 and X2) that would yield a maximum value of
FF10. The R-squared values were found to be 0.968, 0.995
and 0.970 for zero order, Higuchi and Peppas, respectively.
3.7. Stability studies
The stability studies were carried out as per ICH Q1A (R2)
guidelines for the optimized formulation. The formulations
were stored in aluminum foil at 40˚ ± 2˚ C/75 ± 5% RH for
a duration of three months and evaluated for any change in
the appearance, weight variation, drug content and surface
pH. Physical and chemical stability is mentioned in Table 5.
The stability studies indicate no physical change in appearance
and weight variation of fast dissolving ﬁlms (FDF), indicating
that the optimized formulation FF10 was physically stable at
the accelerated conditions. The optimal storage condition of
the formulation was assessed by analyzing the drug content
after the time intervals of 15, 30, 60 and 90 days, drug content
determined was found to be 99.72 and 98.63, at room temper-
ature, respectively after storage for 90 days. The shelf life of
the formulation was found to be 552 days using Sigma Plot
10.0 and the graph is shown below in Fig. 6 (see Fig. 8).
4. Conclusion
The main objective of the present study was to formulate and
evaluate fast dissolving ﬁlms (FDF) of GH. GH, an anti-eme-
tic drug has been selected which has half-life of 5–6 h, the drug
undergoes ﬁrst pass metabolism. Hence in the present work, an
attempt has been made to provide fast dissolving drug delivery
using water soluble polymers with GH as the model drug. The
ﬁlms were prepared using solvent casting method using HPMC
as polymer and propylene glycol as plasticizer. HPMC 15 cps
was selected as polymer on the basis of their matrix forming
properties and inertness, while sodium saccharin is used as a
sweetening agent as it is good for diabetic patients, mint is used
as a ﬂavoring agent and to analyze the usefulness of DOE in
Development and optimization of fast dissolving oro-dispersible ﬁlms of granisetron HCl 201the development and optimization of a fast dissolving ﬁlm of a
model drug employing Box–Behnken statistical design.
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